Lexeo Therapeutics (LXEO) Change in Accured Expenses (2022 - 2026)

Lexeo Therapeutics' Change in Accured Expenses history runs 5 years deep, the most recent figure standing at -$1.1 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 147.17% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at -$7.9 million (down 536.95% YoY), while the FY2025 annual figure was -$4.4 million, down 232.02% from the prior year.
• Change in Accured Expenses came in at -$1.1 million for Q1 2026 at Lexeo Therapeutics, down from -$619000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $5.3 million in Q3 2024 to a low of -$7.1 million in Q2 2025.
• A 5-year average of -$70500.0 and a median of -$763500.0 in 2022 frame the typical range for Change in Accured Expenses.
• On a YoY basis, Change in Accured Expenses climbed as much as 317.16% in 2024 and fell as far as 421.63% in 2024.
• Lexeo Therapeutics' Change in Accured Expenses stood at -$908000.0 in 2022, then plunged by 133.48% to -$2.1 million in 2023, then grew by 9.34% to -$1.9 million in 2024, then surged by 67.79% to -$619000.0 in 2025, then sank by 76.41% to -$1.1 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$1.1 million, -$619000.0, and $996000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison